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Abstract
Objective To investigate the safety and efficacy of N-acetyl-l-leucine (NALL) on symptoms, functioning, and quality of life 
in pediatric (≥ 6 years) and adult Niemann–Pick disease type C (NPC) patients.
Methods In this multi-national, open-label, rater-blinded Phase II study, patients were assessed during a baseline period, 
a 6-week treatment period (orally administered NALL 4 g/day in patients ≥ 13 years, weight-tiered doses for patients 
6–12 years), and a 6-week post-treatment washout period. The primary Clinical Impression of Change in Severity (CI-CS) 
endpoint (based on a 7-point Likert scale) was assessed by blinded, centralized raters who compared randomized video 
pairs of each patient performing a pre-defined primary anchor test (8-Meter Walk Test or 9-Hole Peg Test) during each 
study periods. Secondary outcomes included cerebellar functional rating scales, clinical global impression, and quality of 
life assessments.
Results 33 subjects aged 7–64 years with a confirmed diagnosis of NPC were enrolled. 32 patients were included in the 
primary modified intention-to-treat analysis. NALL met the CI-CS primary endpoint (mean difference 0.86, SD = 2.52, 90% 
CI 0.25, 1.75, p = 0.029), as well as secondary endpoints. No treatment-related serious adverse events occurred.
Conclusions NALL demonstrated a statistically significant and clinical meaningfully improvement in symptoms, function-
ing, and quality of life in 6 weeks, the clinical effect of which was lost after the 6-week washout period. NALL was safe and 
well-tolerated, informing a favorable benefit-risk profile for the treatment of NPC.
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Introduction
Niemann–Pick disease type C (NPC) is a rare (incidence 
1:100,000), prematurely fatal, autosomal recessive, neu-
rovisceral lysosomal storage disease that predominantly 
affects children. However, adolescent and adult-onset 
cases are being increasingly recognized [1]. The disease 
typically begins in early childhood, is chronic, progres-
sive, and severely reduces the quality of life. The presen-
tation of NPC is characterized by broad heterogeneity in 
systemic, psychiatric, and neurological symptoms, which 
depend on the age of onset of neurological symptoms [2]. 
There is broad inter-individual phenotypic variability, 
including age at onset and rate of progression. This renders 
an assembly of well-matched cohorts of NPC patients for 
controlled trials difficult to achieve.
Treatment of NPC is currently limited to reducing the 
rate of disease progression with the substrate reduction 
therapy Miglustat (Zavesca™), approved in the European 
Union and several other countries, but not in the United 
States.
N-Acetyl-l-leucine (NALL) is the l-enantiomer of 
N-acetyl-dl-leucine, a modified, acetylated derivative of a 
natural essential amino acid (Leucine) that has been avail-
able in France since 1957 as a racemate (equal amounts 
of both d- and l-enantiomers) under the trade name Tan-
ganil™ (Pierre Fabre Laboratories, France) as a treat-
ment for acute vertigo. Prior observational studies assess-
ing the effect of N-acetyl-dl-leucine (racemic mixture) 
in patients with NPC suggest a beneficial symptomatic, 
and neuroprotective, disease-modifying effect. In a case 
series, short-term treatment with N-acetyl-dl-leucine was 
found to improve ataxia, cognition, and quality of life in 
12 patients with NPC. Subsequent long-term case series 
and pre-clinical studies demonstrated the neuroprotective, 
disease-modifying effect of treatment in NPC [3–5]. In 
all, the compound was well tolerated with no serious side 
effects.
Animal studies in the NPC mouse model (Npc1−/−) have 
shown the l-enantiomer, i.e. NALL, has clinical benefits 
over the racemate. Treatment with N-acetyl-dl-leucine 
and its enantiomers all significantly reduced ataxia when 
commenced pre-symptomatically (from 3-weeks of age 
onward) and symptomatically (for 1-week treatment, start-
ing at 8 weeks of age). However, only NALL significantly 
delayed the onset of functional decline (gait abnormali-
ties, motor dysfunction), the decline in general health and 
condition, slowed disease progression, and prolonged sur-
vival—whereas the d-enantiomer did not). One mechanism 
of action of NALL that has been implicated for this neu-
roprotective, disease-modifying effect is the activation of 
cerebral glucose metabolism in the cerebellum, correlated 
with enhanced cerebellar activity [5]. Pharmacokinetic 
studies also suggest the d-enantiomer could accumulate 
relative to the l-enantiomer during chronic administration 
of the racemate, with the potential for long-term negative 




The IB1001-201 clinical trial was one of three multi-
national, open-label, rater-blinded trials that utilize a single 
master protocol to investigate NALL (Sponsor Code IB1001) 
for the treatment of three rare, neurodegenerative diseases 
[in addition to NPC, GM2 Gangliosidosis (NCT03759678) 
and Ataxia-Telangiectasia (NCT03759678)]. This IB1001 
master protocol was designed through a collaboration 
between National Regulatory Agencies, leading clinical 
experts, patient organizations, and the industry sponsor 
to address the unique ethical and practical challenges to 
conducting clinical trials for these orphan, heterogeneous 
patient populations. Details of the trial methods, rationale, 
design, and oversight have been previously published [7].
The IB1001-201 clinical trial was separated into two 
study phases to enable the investigation of both the sympto-
matic (“Parent Study”), and long-term (“Extension Phase”) 
safety and efficacy of NALL. The results of the Parent Study 
are reported below. The Extension Phase is ongoing.
Participants
The eligibility criteria have previously been published [7].
Standard protocol approvals, registrations, 
and patient consents
Approval was obtained by the applicable responsible cen-
tral research ethics committees/institutional review boards 
for each center (Ethics Committee of Ludwig Maximilian 
University of Munich (19-135), Slovakia: National Institute 
of Child Diseases Bratislava Ethics Committee (EudraCT 
2018-004431-71), Bellvitge Hospital University Clinical 
Research Ethics Committee (AC001/19), East Midlands—
Derby Research Ethics Committee (259038), Mayo Clinic 
Institutional Review Board (18-011974). Written informed 
consent was obtained for all study participants by the subject 
or, if applicable, their parent or legal representative. The 
study is registered with ClinicalTrials.gov NCT03759639, 
EudraCT number 2018-004331-71, and DR KS-ID: 
DRKS00016567.
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Procedures
Adult and pediatric subjects with a confirmed diagnosis per 
the current recommendations for the detection and diagnosis 
of NPC were [8] recruited at 9 clinical research Universities 
and Hospitals in five countries (Germany, Slovakia, Spain, 
the United States, and the United Kingdom) (Fig. 1). The 
Parent Study consisted of three study periods: a baseline 
period (with or without a study run-in washout from pro-
hibited medications), a treatment period, and a post-treat-
ment washout period, with two patient visits per period. 
Duration of the treatment phase and washout phase were 
42 days (+ 7 days) each, per protocol. No subject randomi-
zation of participants/allocation of participants to different 
study arms occurred (i.e., to different intervention arms). 
However, subject videos obtained from each study period 
were randomized and assessed as the basis of the primary 
endpoint by blinded, centralized raters. The schedule of 
events is reported in Table 1. This study was ongoing during 
the Coronavirus Pandemic (COVID-19), which significantly 
impacted the schedule of events.
At the initial screening visit, patients were classified as 
either “naïve” or “non-naïve” depending on their use of 
prohibited medications (e.g., N-acetyl-dl-leucine) within 
the past 6 weeks. “Non-naïve” patients were given the one-
time opportunity to undergo a minimum of 42 days washout 
before returning for the baseline 1 visit.
During the treatment period, patients aged ≥ 13 years 
or aged 6–12 years weighing ≥ 35 kg received 4 g/day of 
orally administered NALL (powder for suspension in 40 mL 
Fig. 1  Trial profile
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Ora-Blend®) three times per day (2 g in the morning, 1 g 
in the afternoon, and 1 g in the evening). Patients aged 
6–12 years weighing < 35 kg received weight-tiered doses 
two or three times per day based on approximately 0.1 g/
kg/day.
After their final visit of the Parent Study (Visit 6), patients 
could enter a long-term, open-label extension study which 
is ongoing.
Outcomes
The primary endpoint was the novel, functionally relevant 
Clinical Impression of Change in Severity (CI-CS). The 
CI-CS assessment was performed by blinded, centralized 
raters who compared paired videos of each patient perform-
ing a “primary anchor test” [either the 8 Meter Walk Test 
(8MWT) or 9 Hole Peg Test-Dominant Hand (9HPT-D)] 
at baseline (Visit 2), end of treatment (Visit 4), and end of 
washout (Visit 6) study visits. Blinded to the time point of 
each video in each pair, the raters made an objective com-
parison scored on a 7-point Likert scale of the change in the 
severity of the patient’s neurological signs and symptoms 
from Video 1 to Video 2. Details of CI-CS administration 
and assessment have been previously published [7].
Each patient’s primary anchor test (8MWT or 9HPT-D) 
was selected by the Principal Investigator at Visit 1 based on 
the patient’s unique clinical symptoms to better ensure the 
clinical relevancy of the primary outcome assessment. The 
anchor tests were filmed in a standardized way at each visit 
and uploaded for centralized review. A pool of three board-
certified neurologists performed the central video analysis. 
Two “primary raters” were responsible for the initial com-
parison of the video pairs. For cases where the two initial 
reviewers differed in their assessment of the primary CI-CS 
score by more than one (1) point, the third rater acted as an 
adjudicator.
Table 1  Schedule of assessments
Period Baseline period Treatment period Wash-out period Early term
Duration of the whole period 1 day 2 weeks 6 weeks 6 weeks 1 day
Visit number Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6/EOS ET
Name of the visit Screening/Bsl 1 Baseline 2 Treatment 1 Treatment 2 Washout 1 Washout 2 ET
Timeline (days) Day-14 Day 1, Start IMP Day 28 Day 42 Day 70 Day 84 XX
Visit window allowed na + 7 days + 7 days + 7 days + 7 days + 7 days na
Patient information and informed consent 
process
X
Inclusion/exclusion criteria, medical his-
tory, patient demographics
X X
Classify patient as “Naïve” or “Non-
naïve”
X
Documentation of therapy and concomi-
tant medications
X X X X X X X
Vital signs X X X X X X X
12-lead electrocardiogram (ECG) X X X X
Urine test for N-Acetyl-d-Leucine X X X X X
Blood safety laboratory tests and urinaly-
sis
X X X X X X X
Blood sample for sparse PK X X X X X X X
Quality of Life EQ-5D X X X X X X X
Scale for Ataxia Rating (SARA) X X X X X X X
Modified Disabling Rating Score (mDRS) X X X X X X X
Scale for Spinocerebellar Ataxia Func-
tional Index (SCAFI)
X X X X X X X
CI-CS Anchor Test Video Record X X X X X X X
Clinical Global Impression of Severity 
(CGI-S)
X X X X X X X
Clinical Global Impression of Change 
(CGI-C) by Physician, Caregiver, 
Patient
X X X
Documentation of AEs X X X X X X X
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The raters assessed: “Compared to the first video, how 
has the severity of the patient’s performance on the 8MWT 
or 9HPT-D changed (improved or worsened) as observed 
in the second video?” The CI-CS assessment was based 
on a 7-point Likert scale ranging from + 3 (significantly 
improved) to − 3 (significantly worse).
Secondary assessments were analyzed between two time 
points: (1) baseline (Visit 2) to the end of treatment (Visit 4); 
(2) the end of treatment (Visit 4) to the end of post-treatment 
washout (Visit 6).
To evaluate the overall neurologic status in NPC disease, 
the modified Disability Rating Scale (mDRS) was applied, 
consisting of 6 subdomains (ambulation, manipulation, 
Seizures, Language, Swallowing, Ocular movements) [9]. 
Cerebellar function evaluations were administered, includ-
ing: (1) the Scale for the Assessment and Rating of Ataxia 
(SARA), an 8-item clinical rating scale (gait, stance, sit-
ting, speech, fine-motor function, and coordination; range 
0–40, where 0 is the best neurologic status and 40 the worst) 
[10]; and (2) the Spinocerebellar Ataxia Functional Index 
(SCAFI), comprising 8-m walking time performed by hav-
ing patients walk twice, as quickly as possible, from one line 
to another excluding turning, the 9-Hole Peg Test (9HPT) 
with the dominant and non-dominant hand, and the number 
of “PATA” repetitions over 10 s (PATA) [11].
Subjective impairment and quality of life were evalu-
ated by using the Clinical Global Impression of Severity 
and Improvement Scale (completed by the Investigator, Car-
egiver, and Subject) [12], the EuroQol (EQ) 5Q-5D-5L/Y 
questionnaire and the visual analog scale (VAS) [13].
Safety assessments included adverse event monitoring, 
clinical laboratory testing, and sparse pharmacokinetic sam-
pling, and collecting vital signs and electrocardiograms.
Randomization and masking
CI-CS anchor test videos (8MWT and 9HPT-D) were sub-
mitted directly from trial sites to a third-party vendor, Med-
pace Core Laboratories (MCL). For each patient, MCL gen-
erated a random number (1–6) via RANDOM.ORG which 
corresponded to a video analysis order sequence (Supple-
mentary Table 1). Once all applicable videos for a patient 
had been obtained, MCL assigned the patient’s videos to this 
randomization sequences, generating 3 randomized video 
pairs for the CI-CS assessment. These 3 CI-CS assessments 
were released to the blinded raters for review via the secure 
MCL Clintrak Imaging System Portal.
Only the MCL IB1001 study team had access to the ran-
domization sequences. To ensure that central raters were 
blinded to any patient identifiers, each patient video was 
assigned a “barcode” and “reading number” that identified 
the video throughout the central review process. Usage of 
the “barcode” and “reading number” blinded the raters to 
any information (i.e., subject ID, DOB, visit identifier) that 
might have introduced bias during the central review.
Statistical analysis
The primary endpoint was defined as the numerical differ-
ence of the CI-CS value for the treatment period (Visit 2 
versus Visit 4) minus the CI-CS value for the washout period 
(Visit 4 versus Visit 6). This endpoint appropriately cap-
tured improvement in symptoms during the treatment period 
together with worsening of symptoms during the washout 
period. A sample size of 30 patients would provide the trial 
with 76% power, at a one-sided significance level of 5%, 
to detect a mean effect of at least 0.45 in the primary end-
point (assuming a standard deviation 1.02). The 76% power 
was a consequence of pragmatic considerations in relation 
to clinically relevant outcomes on the CI-CS scale follow-
ing treatment with IB1001 and subsequent washout and was 
viewed as being acceptable for the purpose of assessing a 
true treatment-related effect. With respect to the primary and 
secondary outcome measures, this would provide a sufficient 
dataset, taking account of the rarity of these neurological 
conditions, and was viewed as being acceptable for assessing 
a true treatment-related effect. The primary analysis was per-
formed according to the modified intention-to-treat (mITT) 
principle, used to estimate the treatment effect regardless of 
early patient discontinuation and provides a perspective of 
the treatment effect across the entire population. The mITT 
analysis set was defined as all patients who receive at least 
one dose of the study drug and with one video recording dur-
ing the baseline period (Visit 1 or 2, or both) and treatment 
period (Visit 3 or Visit 4, or both). The mITT analysis uti-
lized a last observation carried forward approach for the pri-
mary CI-CS endpoint which implies that the CI-CS value for 
Visit 4 to Visit 6 is assigned the value 0 (stable) if both vid-
eos from the washout period (Visit 5 and Visit 6) were not 
available. The analysis of the primary endpoint was based 
on a single sample one-sided Wilcoxon comparing the mean 
of the CI-CS differences with zero. The null hypothesis is 
that the mean is ≤ 0, with the alternative hypothesis that this 
mean is > 0 and the test will be conducted at the one-sided 
5% significance level. Non-parametric 90% confidence inter-
vals were constructed using the Hodges–Lehmann method 
[14]. Secondary endpoints were evaluated either statistically 
based on a single sample t-test or a single sample Wilcoxon 
signed rank test or descriptively, as pre-defined in the statis-
tical analysis plan (SAP). There was no formal hierarchical 
structure defined for the secondary endpoints and results 
on these endpoints should therefore be viewed as explora-
tory. For each of the primary and secondary endpoints, there 
were separate analyses within key subgroups pre-defined in 
the SAP. These subgroups are listed in Fig. 2. The safety 
analysis set (SAF) consisted of all patients who received at 
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least one dose of the study drug. The safety, integrity, and 
feasibility of the trial were monitored by an independent 
data safety monitoring board (DSMB) consisting of three 
independent, non-participating members (including two cli-
nicians and a statistician).
Results
Between 04 September 2019 and 30 January 2020, thirty-
four participants were screened, and thirty-three subjects 
were enrolled per protocol. The demographic and base-
line clinical characteristics of the patients are presented in 
Table 2.
Thirty-two patients qualified for the primary mITT analy-
sis set (96.9%), which included all patients dosed who had 
at least one treatment visit (Visit 3 or Visit 4). One patient 
was withdrawn after Visit 2 due to an unrelated adverse 
event (epileptic seizures, for which the patient needed to 
commence a medication the PI believed could confound the 
safety and efficacy analysis of the trial). One patient was 
withdrawn between Visit 3 and Visit 4 following an unre-
lated serious adverse event (fall, resulting in head injury/
trauma and two broken ribs). The median duration of NALL 
treatment was 43 days (range: 35–133), with a mean dura-
tion of exposure of 51.7 days. The COVID-19 pandemic 
impacted the duration of treatment/post-treatment washout 
for select patients, and patients were dosed/on washout until 
it was safe and feasible to conduct an on-site end of treat-
ment/washout visit in adherence with all COVID-19 local 
regulations. These deviations due to COVID-19 are reflected 
by the limited size of the per-protocol population (n = 18). 
Thirty-one patients (93.9%) completed the Parent Study 
(Visit 6) (last patient last visit occurred 05 August 2020).
The CI-CS primary endpoint of the study reached sta-
tistical significance with p = 0.029 with mean value = 0.86 
Fig. 2  Forest plot for CI-CS scores for pre-defined subgroup analysis, 
based on the mITT population. The lines and dots in blue represent 
the change per subgroup on the CI-CS scores during the treatment 
period: Visit 4 (end of treatment) vs. Visit 2 (baseline). The lines and 
dots in orange represent the change per subgroup on the CI-CS scores 
during the washout period: CI-CS scores visit 6 (end of washout) vs. 
Visit 4 (end of treatment). The dots represent the pseudo-medians or 
Hodges–Lehmann estimators, the horizontal lines represent the 90% 
confidence intervals. LCL lower confidence limit, UCL upper con-
fidence limit. For some subgroups the number of patients was too 
small to calculate the LCL and/or UCL, in that case, the result is 
presented as missing and no line presenting the confidence interval 
is drawn. No last observation carried forward (LOCF) approach was 
used for this figure. Only values from patients with reported data are 
included.
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(SD = 2.52, median = 1.0) and Hodges–Lehmann 90% confi-
dence interval (CI) (0.25, 1.75). There were no missing val-
ues for CI-CS for the treatment period although there were 
four missing values for CI-CS during the washout period 
(Fig. 3A).
The CI-CS component for the treatment period (Visit 
4 versus Visit 2) had a mean value of 0.48 (SD = 1.34 
median = 1.0), showing on average an improvement in the 
patients’ condition over that period, while the CI-CS com-
ponent for the washout period (Visit 6 versus Visit 4) had a 
mean value of -0.38 (SD = 1.45, median = − 0.25) showing 
on average a worsening. There was no difference observed 
between the CI-CS comparing the baseline and washout 
visits (Visit 6 versus Visit 2): mean value 0.063 (SD = 1.32, 
median = 0, n = 30). This reinforced the treatment effect, but 
also demonstrated the absence of a learning effect on the 
CI-CS anchor tests. The CI-CS was demonstrated to be a 
reliable instrument, with high inter-rater consistency (0.80 
correlation).
A Forest plot (Fig. 2) is included to display results for 
the primary endpoint in the pre-defined subgroups show-
ing Hodges–Lehman median estimates and corresponding 
90% confidence intervals calculated where possible. There is 
some variation as would be expected given the small sample 
sizes but there is no evidence that would suggest a differ-
ential treatment benefit across the population as a whole. 
Instead, across all subgroups, there was a consistent trend 
of improvement during treatment and deterioration during 
the washout.
The mean total SARA score at baseline (Visit 2) was 
14.47 (SD = 7.14, median = 12.74, n = 32) and encompassed 
a full range of disease-severity (min = 5, max = 33). The 
mean change in SARA score during the treatment period 
(Visit 2 to Visit 4) was − 1.19 (SD = 2.02, median = − 1.00, 
n = 31) with 90% CI (− 1.75, − 0.50) p = 0.001, demon-
strating an improvement on cerebellar signs and neurologi-
cal symptoms. The mean change in SARA score during the 
washout period (Visit 4 to Visit 6) was 1.45 (SD = 2.56, 
median 0.75, n = 28) with 90% CI (0.50, 2.00), p = 0.002, 
showing a deterioration (Fig. 3B). There was no differ-
ence observed between the baseline visit to the washout 
visit (Visit 2 to Visit 6); the mean change in score was 0.25 
(SD = 2.60, median = 0, n = 28) with 90% CI (1.1, − 0.59) 
p = 0.308. This further reinforced the treatment effect, but 
also demonstrated the absence of a learning effect on the 
SARA subdomains.
The CGI-Change is presented around a reference value 
of 0 = no change, so that for example − 1 = minimally 
worse and + 1 = minimally improved. The investigator, 
caregiver, and patient CGI-C were consistent and showed 
an average improvement during the treatment period and 
deterioration during the washout period (Fig. 3C). For 
Table 2  Demographics and baseline characteristics






Ethnicity, n (%) Asian 1 (3.0%)
White 30 (90.9%)
Other 2 (6.1%)
Gender, n (%) Male 24 (72.7%)
Female 9 (27.3%)
Age Group, n (%) Paediatric (< 18 years) 10 (30.3%)
Adult (≥ 18 years) 23 (69.7%)
Dose, n (%) Age 6–12 years—15 to < 25 kg—2 g/day 1 (3.0%)
Age 6–12 years—25 to < 35 kg—3 g/day 2 (6.1%)
Age 6–12 years →  = 35 kg—4 g/day 2 (6.1%)
Age ≥ 13 years—4 g/day 28 (84.8%)
Geographic Location, n (%) USA 2 (6.1%)
Europe 31 (93.9%)
Miglustat at baseline, n (%) Yes 30 (90.9%)
No 3 (9.1%)
Selected primary anchor test, n (%) 8 Meter Walk Test (8MWT) 12 (36.4%)
9 Hole Peg Test-Dominant Hand (9HPT-D) 21 (63.6%)
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the investigator’s CGI-C, the mean change from Visit 2 
to Visit 4 was 0.6 (SD = 0.9, median = 0, n = 31) with 90% 
CI (0.5, 1.0) p < 0.001 while the mean change from Visit 
4 to Visit 6 was − 0.5 (SD = 0.9, median = 0, n = 28) with 
90% CI (− 1.0, 0) p = 0.006. For the caregiver’s CGI-C, 
the mean change from Visit 2 to Visit 4 was 0.6 (SD = 1.0, 
median = 0, n = 30) with 90% CI (1.0, 0.0) p = 0.005, 
while the mean change from Visit 4 to Visit 6 was − 0.4 
(SD = 1.1, median = 0, n = 27) with 90% CI − 1.0, 0.0) 
p = 0.038. For the patient’s CGI-C, the mean change from 
Visit 2 to Visit 4 was 0.7 (SD = 1.0, median = 0.5, n = 25) 
with 90% CI (0.5, 1.0) p = 0.003, while the mean change 
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from Visit 4 to Visit 6 was − 0.4 (SD = 0.9, median = 0, 
n = 25) with 90% CI (− 0.5, 0.0) p = 0.034.
The mean total SCAFI score at baseline (Visit 2) was 
− 0.3011 (SD = 1.0405, median = − 0.1362, n = 32). The 
score during the treatment period showed a trend towards 
improvement, with a mean change (Visit 2 to Visit 4) of 
0.0995 (SD = 0.3058, median = 0.0890, n = 30) with 90% 
CI (− 0.0123, 0.1777) p = 0.084. The mean change in score 
during the washout period (Visit 4 to Visit 6) was 0.0076 
(SD = 0.3584, median −  0.0621, n = 26) with 90% CI 
(− 0.1269, 0.1031) p = 0.315. There was a trend for improve-
ment on the 8MWT (mean − 1.093, 90% CI − 1.53, 0.05, 
p = 0.065) and PATA test (mean 0.95, 90% CI 0.0, 1.75, 
p = 0.076) on medication. As reported in other neurological 
disorders, the quantifiable time-based SCAFI assessments 
may not best capture clinically meaningful changes in func-
tioning or quality of life; hence, the CI-CS assessment was 
developed [15].
The mean mDRS at baseline was 0.467 (SD = 0.155, 
median = 0.458, n = 32). Change from baseline through to 
Visit 4 showed a small improvement in terms of disability 
on average with a mean change of − 0.012 (SD = 0.050, 
median = 0, n = 31), 90% CI (− 0.021, 0.0) p = 0.121 with 
a mean change from Visit 4 to Visit 6 (washout) of 0.016 
(SD = − 0.051, median = 0, n = 28), 90% CI (0.0, 0.042), 
p = 0.056 on average showing a slight worsening in terms 
of disability.
A treatment-emergent adverse event (TEAE) was any 
adverse event (AE) that appeared or worsened after study 
treatment began (i.e. in the treatment or washout period). 
The distribution of TEAEs is shown in Supplementary 
Table 2. There were no AEs with an incidence > 10%. Seven 
related AEs were reported for 4 patients, including: flatu-
lence, diarrhoea, increased feeling of hunger, rash (twice 
for 1 patient), and aggressive behaviour accompanied by 
restlessness. The events were transient and manageable. No 
serious adverse reactions were reported. No deaths occurred 
during the study. Results of plasma and urine tests, vital 
signs, and ECG recordings were normal or rated as clinically 
non-significant. Adherence was high as shown by treatment 
compliance and the regular urine analyses for prohibited 
medication.
Discussion
Here we report the results of a Phase II clinical trial inves-
tigating the safety and efficacy of the modified amino acid 
NALL for NPC disease in patients aged 6 years or older. 
The major findings of the IB1001-201 trial are: first, NALL 
improved symptoms, including gait and stance, upper 
extremity function, and fine motor skills, which worsened 
during the post-treatment washout. Second, consistent with 
its pharmacological action, NALL improved cerebellar signs 
and functioning after 6 weeks. Third, improvement of neu-
rological status was observed across all demographics of 
patients (age, gender, age of onset, disease severity, etc.) 
establishing the rationale for NALL to be used as a treatment 
for all NPC patients. Fourth, the low frequency (7 related 
AEs in 4 patients of 32 participants) and the transient, mild 
nature of these AEs inform a favorable benefit-risk profile.
Methodologically, to elaborate a novel clinical endpoint, 
the CI-CS based on videos of the 8MWT or the 9HPT-D 
was used which was rated (0 ± 3) by blinded, centralized 
neurologists. In addition to reducing detection and perfor-
mance bias for the primary endpoint, the blinded CI-CS 
served as a metric of clinical importance that could not be 
obtained from the traditional timed assessments. Instead, 
raters evaluated clinically meaningful changes in patient’s 
neurological manifestations which correlate to their level 
of functioning and quality of life, such as the accuracy and 
fluidity of movements, spasticity, ataxia, and dystonia for the 
9HPT-D, and changes in gait patterns such as balance and 
postural stability, variability, asymmetry, ataxia, and support 
for the 8MWT [7].
Of note, 93.8% of patients were on the standard of care 
agent Miglustat. The administration of NALL therefore 
showed significant effects beyond Miglustat for the signs and 
symptoms of NPC. This is in line with the previous obser-
vational studies that indicated the additive effect of NALL 
with Miglustat [3, 4], and studies demonstrating synergistic 
effects of NALL and Miglustat [5].
NALL’s positive treatment effects directly corre-
late to its pharmacological action. Animal studies in an 
Npc1−/− mouse model show NALL significantly reduces 
ataxia when treatment is initiated either symptomati-
cally (from 8 weeks of age) or pre-symptomatically (from 
3 weeks of age) [5]. These in vivo studies further show 
Fig. 3  Results of the primary and key secondary endpoints. All analy-
sis based on the mITT population. For each figure, the left-hand col-
umn (blue) illustrates CI-CS results comparing baseline to the end of 
the treatment period; the right-hand column (orange) illustrates the 
CI-CS results comparing the end of the treatment period to the end 
of the washout period. The vertical extent of the column represents 
the 90% Hodges–Lehman (HL) confidence interval of the CI-CS; a 
solid line is used to indicate the Hodges–Lehman median estima-
tor, and a cross symbol indicates the Mean response. A Results of 
the primary endpoint: Clinical Impression of Change in Severity 
(CI-CS), based on a 7-point scale, ranging from −  3, “significantly 
worse”, 0, “no change”, to + 3 to “significantly improved”. B Results 
on the secondary endpoint: Scale for the Assessment and Rating 
of Ataxia (SARA); C results on the secondary endpoint: Clinical 
Global Impression of Change—Physician, Caregiver, Patient; based 
on a 7-point scale, ranging from −  3, “significantly worse”, 0, “no 
change”, to + 3 to “significantly improved”; D results on the second-
ary endpoint: Modified Disability Rating Scale (mDRS); E results 
on the secondary endpoint: Spinocerebellar Ataxia Functional Index 
(SCAFI)
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NALL can restore neuronal function and protect against/
delay disease progression in multiple neurological brain 
circuits. Altered glucose and antioxidant metabolism and 
reduction of cerebellar inflammation have been implicated 
as potential mechanisms of action [5, 16]. Similar neu-
roprotective, disease-modifying effects of acetyl-leucine 
were found in an analogous animal model of another lyso-
somal storage disease, the Sandhoff mouse [17]. Notably, 
the dosage used in these in vivo studies (0.1 g/kg/day) is 
roughly equivalent to the dose used in previous observa-
tional clinical studies with the racemate and the IB1001-
201 clinical trial.
The clinical manifestations of this, as demonstrated in 
the IB1001-201 clinical trial, were visualized and captured 
in terms of improvements or stabilization in very different 
processes such as ambulation, fine motor skills, speech, 
and cognition. This is also consistent with previous obser-
vational studies with N-acetyl-leucine where treatment of 
4–6 weeks significantly improved symptoms, function-
ing, and quality of life in 12 NPC patients, and where 
long-term treatment of at least 1-year lead to a significant 
reduction in disease progression and clinical improvement 
in the majority of patients, indicative of a neuroprotective, 
disease-modifying effect [3, 4].
The IB1001-201 parent study has several limita-
tions. First, it was not placebo-controlled. As previously 
reported, the widespread, unlicensed use of the commer-
cially available racemate (N-acetyl-dl-leucine; Tanga-
nil™) and even, patient’s access to chemical grade sub-
stitutes of NALL, within the NPC is well-known. This 
severely limited the feasibility of including a placebo-con-
trol, given patients and families reluctance to participate 
in a study where they would be required to washout from 
this unlicensed medication and receive an inactive treat-
ment for even 50% of the time [7]. To ensure the study 
remained well-controlled and minimized bias, controls 
were put in place for the study—including the central-
ized, blinded review paradigm and use of intra-patient 
internal control—to enable a complete assessment of the 
scientific integrity and validity of the results. To mini-
mize potential patient expectation or investigator bias, all 
aspects of the administration and video recording of the 
CI-CS anchor tests were standardized to ensure the qual-
ity of videos assessed by the blinded raters. Before any 
patient visit, site personnel were trained on these detailed 
protocols, including precise verbal instructions, encour-
agement, break times between test trials, and instructions 
on which trial to record. Given that the majority of NPC 
patients enrolled in the IB1001-201 clinical trial featured 
severe physical impairments with regard to both their fine 
motor skills as well as balance and gait, and mild to sig-
nificant levels of cognitive impairment, the potential for 
a placebo-effect which significantly altered neurological 
signs and symptoms–the basis of the CI-CS assessment—
was considered minimal, ensuring the interpretability of 
the blinded-raters’ CI-CS assessments.
Second, the novel CI-CS primary endpoint has not been 
previously used or yet validated. It was implemented, how-
ever, due to the methodological limitations of applying 
pre-existing ataxia scales in heterogeneous diseases, in 
which cases, the scales may be too broad and therefore 
not sensitive to capture small but meaningful functional 
changes [7, 18]. The validated NPC Clinical Severity Scale 
is only validated to measure disease progression after a 
minimum of 1 year; thus, it is not sensitive enough to cap-
ture or measure change after 6-weeks [19]. Accordingly, 
the CI-CS was developed to be a more clinically relevant 
endpoint capable of detecting clinically meaningful treat-
ment effects. All aspects of the CI-CS were standardized 
and well-defined, and the CI-CS was demonstrated to be 
a reliable instrument, with high inter-rater consistency.
Third, this study was limited to an investigation of the 
symptomatic effect of NALL treatment; data from the 
ongoing Extension Phase will provide further insights 
into the impact on disease progression and long-term 
safety. Given that the heterogeneous symptoms of NPC 
are serious, debilitating, and significantly impact quality 
of life, managing the neurological symptoms of NPC rep-
resents an important and meaningful treatment paradigm 
for patients.
In conclusion, this study provides strong support for 
the use of NALL as a symptomatic treatment for NPC. 
Consistent with previous non-clinical and observational 
clinical studies, NALL demonstrated a significant and clin-
ically meaningful improvement of neurological symptoms, 
functioning, and quality of life in pediatric and adult NPC 
patients and was safe and well-tolerated, contributing to 
a favorable benefit-risk profile for the treatment of this 
serious, debilitating disease. Given NPC is a progressive, 
life-threatening condition with limited or no approved 
medicinal treatments, and no symptomatic treatments, 
and considering the totality of the evidence available for 
NALL, there is an urgency for treatment to be available 
for patients before the window of therapeutic opportunity 
is lost.
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